# A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06778967` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06778967](<https://clinicaltrials.gov/study/NCT06778967>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06778967

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1133 participants.

## Technical summary

Registry record NCT06778967. Randomized; no masking; primary purpose treatment. Start 2025-02-13 (actual); primary completion 2026-09-18 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1133 participants (enrolled count; ClinicalTrials.gov record NCT06778967, source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)
- Started: 2025-02-13 (actual) (ClinicalTrials.gov record NCT06778967, source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2026-09-18 (actual) (ClinicalTrials.gov record NCT06778967, source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)
- Completion: 2026-09-18 (actual) (ClinicalTrials.gov record NCT06778967, source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06778967, source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06778967-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
- Acronym: Optimum 2
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): GZR18
- Intervention (Drug): semaglutide
- Lead sponsor: Gan & Lee Pharmaceuticals.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Gan & Lee Pharmaceuticals. (`cardio:org-gan-lee-pharmaceuticals`)

## Provenance

Content hash: 337c1631d380b7312a524723ccfcd234a8ff67c65d9eb95f76ddebaf5502a76f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
